[et_pb_section fb_built=”1″ _builder_version=”4.9.7″ background_image=”https:\/\/allogenbio.com\/wp-content\/uploads\/2021\/10\/shutterstock_1850161345-scaled.jpg” min_height=”306.2px” custom_padding=”||0px|||” hover_enabled=”0″ max_width=”100%” width=”100%” sticky_enabled=”0″][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.7″ _module_preset=”default” min_height=”133px” custom_margin=”||-32px|||” custom_padding=”||0px|||”][et_pb_row _builder_version=”4.9.7″ _module_preset=”default”][et_pb_column _builder_version=”4.9.7″ _module_preset=”default” type=”4_4″][et_pb_text _builder_version=”4.9.7″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″ custom_margin=”-52px|||||”]<\/p>\n
Timothy G. Dixon \u2013 CEO and Chairman<\/b><\/p>\n<\/div>\n Mr. Dixon currently also serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc., CEO and Chairman of \u00a0ALS Biologics, Inc., Breathe Biologics, Inc., CTE Biologics, Inc., Epilepsy Bio, Inc., Res Nova Bio, and VasoSome Vascular, Inc., \u00a0all subsidiaries of TSOI. Mr. Dixon previously served as Chairman of Campbell Neurosciences, Inc., President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration (FDA), as well as many international regulatory bodies. Mr. Dixon is inventor and co-inventor of 75+ patents and patents pending.<\/p>\n<\/div>\n Feng Lin, MD, Ph.D., \u2013 Chief Scientific Officer<\/strong> Dr. Lin received his postdoctoral training at the Sanford-Burnham Medical Research Institute and his MD and Ph.D. at the Xiangya Medical School of Central South University, China. He has authored over 20 peer-reviewed scientific publications, including several in top journals such as Science, Cell, and Cancer Cell. He holds several patents.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" [et_pb_section fb_built=”1″ _builder_version=”4.9.7″ background_image=”https:\/\/allogenbio.com\/wp-content\/uploads\/2021\/10\/shutterstock_1850161345-scaled.jpg” min_height=”306.2px” custom_padding=”||0px|||” hover_enabled=”0″ max_width=”100%” width=”100%” sticky_enabled=”0″][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.7″ _module_preset=”default” min_height=”133px” custom_margin=”||-32px|||” custom_padding=”||0px|||”][et_pb_row _builder_version=”4.9.7″ _module_preset=”default”][et_pb_column _builder_version=”4.9.7″ _module_preset=”default” type=”4_4″][et_pb_text _builder_version=”4.9.7″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″ custom_margin=”-52px|||||”] Timothy G. Dixon \u2013 CEO and Chairman Mr. Dixon currently also serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc., CEO and Chairman of \u00a0ALS […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-41","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/pages\/41","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/comments?post=41"}],"version-history":[{"count":3,"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/pages\/41\/revisions"}],"predecessor-version":[{"id":49,"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/pages\/41\/revisions\/49"}],"wp:attachment":[{"href":"https:\/\/allogenbio.com\/index.php\/wp-json\/wp\/v2\/media?parent=41"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nDr. Lin has a stellar track record of drug development in the area of immunology and immuno-oncology having worked with the public company Inovio Pharmaceuticals, where he developed technologies for gene delivery and therapeutic DNA vaccines against cancer and infectious diseases in both R&D and clinical settings. Subsequently, Dr. Lin served as Director of Chinese Operations for MediStem Inc, which was acquired by Intrexon in May 2014. It was the rapid clinical translation model developed by Dr. Lin at MediStem that resulted in the company\u2019s accelerated FDA clearance to begin clinical trials, which resulted in the sale of the company. Dr. Lin also serves as Chief Scientific Officer of Therapeutic Solutions International, Inc.<\/p>\n